

GODAVARI BIOREFINERIES LIMITED

NEUTRAL

IPO Report

Snapshot

Company is one of the manufacturers of ethanol based chemicals in India and is an integrated bio-refinery in India with an installed capacity of 570 KLPD for manufacturing ethanol as at June 30, 2024. Company is one of India's largest producers of ethanol in terms of volume as of March 31, 2024 . As on March 31, 2024, company was also the largest manufacturer of MPO worldwide in terms of installed capacity, one of only two manufacturers of natural 1,3 butylene glycol and the only company in India to manufacture bio ethyl acetate. Company have also set up India's first bio-based EVE manufacturing facility in India as on March 31, 2024.

VALUATION

Company is bringing the issue at price band of Rs 334-352 per share at p/e multiple of 146x on post issue annualized FY24 PAT basis.

Company is one of the manufacturers of ethanol-based chemicals in India and one of India's largest producers of ethanol in terms of volume. Company has integrated biorefinery with an installed capacity of 570 KLPD for manufacturing ethanol as at March 31, 2024 . Company has diversified product portfolio and wellestablished relationship with a diversified marquee customer base across industries and geographies. Company has welldeveloped in-house research and development capabilities and member of the Somaiya group and experienced promoter, board of directors, key managerial personnel and senior management Hence Looking after all above along with high valuations at current level, we are "Neutral" on issue.

Price Band (Rs./Share)	334-352		
Opening date of the issue	23 rd Oct '2024		
Closing Date of the issue	25 th Oct '2024		
No of shares pre issue	4,19,43,023 Eq Shares		
Issue Size	Rs 543-555 Cr		
Fresh issue	Rs 325 Cr		
Offer For Sale	65,26,983 Equity Shares		
Face Value (Rs/ share)	Rs 10/share		
Bid Lot	42		
BIDDING DETAILS			
QIBs (Including Anchor)	50% of the offer (Approx 81,28,759 Eq Shares)		
Non-Institutional	15% of the offer (Approx 24,38,629 Eq Shares)		
Retail	35% of the offer (Approx 56,90,132 Eq Shares)		
Lead managers	Equirus Capital, SBI Capital Markets		
Registrar to the issue	Link Intime India Pvt. Ltd		

WHAT WE LIKE

Company is a manufacturer of Ethanol-based Chemicals and is one of the largest producers of Ethanol in terms of volume

22nd Oct '24

Company have also set up India's first bio-based EVE manufacturing facility in India as on March 31, 2024. Company's customers for ethanol include oil marketing companies pursuant to the ethanol blended petrol programme of the Government of India (the "EBP Program"). According to the Frost & Sullivan Report, the Indian ethanol market is projected to grow from USD 7.0 billion in 2023 to USD 17.5 billion by 2028, exhibiting a CAGR of 20.0% during 2023-2028, on the back of increasing ethanol use in applications such as fuel additives, disinfectants, and beverages.

Diversified product portfolio and well-established relationship with a diversified marquee customer base across industries and geographies

Company's customers include marquee players such as Hershey India Pvt Ltd, Hindustan Coca-Cola Beverages Private Limited, M/s Karnataka Chemical Industries, M/s Techno Waxchem Pvt Ltd, LANXESS India Private Limited, IFF Inc., Khushbu Dye Chem Pvt Ltd, and Privi Speciality Chemicals Limited, as well as major oil marketing companies.

Company is a member of the Somaiya group and have an experienced Promoter, Board of Directors, Key Managerial Personnel and Senior Management

Company is a member of the Somaiya group, which has diversified interests in inter alia the biorefinery, agricultural research, education and healthcare industries. Company is able to leverage the experience, capabilities and reputation of the Somaiya group in company's business operations. Company's Individual Promoter, Samir Shantilal Somaiya, who is also Chairman and Managing Director, plays a significant role in the development of company's business.



GODAVARI BIOREFINERIES LIMITED

COMPANY BACKGROUND

Company's diversified product portfolio comprises of bio-based chemicals, sugar, different grades of ethanol and power. These products find application in a range of industries such as food, beverages, pharmaceuticals, flavours & fragrances, power, fuel, personal care and cosmetics. Company has the widest portfolio of bio-based products in India. Company utilise sugarcane as a feedstock to manufacture a wide range of products, including sugar, ethanol, bio-based chemicals and power and were among the first few companies in India to utilise sugarcane juice and syrup for the production of ethanol . Company continuously strive to improve the valorisation of sugarcane through development of down-stream products and increase the diversion of sugarcane towards value added products. For instance, company have been successful in manufacturing a wide range of bio-based chemicals such as ethyl acetate, bio-ethyl acetate, MPO, 1,3 butylene glycol, crotonaldehyde, acetaldehyde, bio-acetic acid, butanol, EVE, and paraldehyde. Company is also in the process of exploring the utilisation of grains to manufacture grain-based ethanol.

Company's Sameerwadi Manufacturing Facility with a crushing capacity of 18,000 TCD as on June 30, 2024, according to the Frost & Sullivan Report, Company's sugar mill, is among the top fifteen sugar complexes in India in terms of crushing capacity. Company also have an environmental clearance to expand crushing capacity up to 25,000 TCD. Through its long history of purchasing sugarcane and continued support provided to the farmers, company have established strong relationships and goodwill among the farmers. Further, company is one of India's largest producers of ethanol in terms of volume as of March 31, 2024 (source: Frost & Sullivan Report) with an installed capacity of 570 KLPD as at June 30, 2024.

The rectified spirits manufactured by company is converted into different grades of ethanol including fuel ethanol, pharma grade ethanol and extra neutral alcohol ("Ethanol"). In order to improve the valorisation of sugarcane and in light of the government initiatives for increasing fuel ethanol blending, company intend to expand its distillery capacity from 600 KLPD (as at June 30, 2024) to 1,000 KLPD and have obtained environmental clearance for such expansion. Further, Company proposes to commence the manufacturing of 2 nd generation Ethanol from bagasse, a by-product of sugar, to further improve the utilisation of available feedstock for company's distillery. Company have entered into a memorandum of agreement with the Centre for High Technology, an administrative control of the Ministry of Petroleum & Natural Gas, Government of India in relation to grant of financial assistance to Company for a maximum amount of ₹150.00 million for the proposed installation of a 2G ethanol plant at its Sameerwadi Manufacturing Facility.

The chemicals manufactured by company comprise of Ethanol-based chemicals such as ethyl acetate, bio-ethyl acetate, MPO, 1,3 butylene glycol, crotonaldehyde, acetaldehyde, bio-acetic acid, butanol, EVE, and paraldehyde (collectively, the "Bio-based Chemicals"). The Bio-based Chemicals manufactured by company find application in various industries, including the personal care and cosmetics, flavour and fragrance, food, fuel, paints and coatings and pharmaceutical industries, while the Ethanol manufactured by company is sold to oil marketing companies and also find application in the beverages, pharmaceutical and chemical industries. Company have also received environmental clearance to expand its existing capacities and to manufacture a wider range of speciality chemicals including cellulose and its derivatives.

Company have consistently invested in R&D and technology and have pursuant to its assessment of demand in the market and its customers, sought to implement them at itsr Manufacturing Facilities. During the three months ended June 30, 2024 and Fiscals 2024, 2023 and 2022, company have incurred research and development expenditure aggregating to ₹24.84 million, 143.50 million, 170.06 million, and 133.62 million respectively, constituting 0.44%, 0.85%, 0.85% and 0.80%, respectively, of company's total expenses. Company have three research and development facilities (the "R&D Facilities") which are registered with the Department of Scientific and Industrial Research, Government of India ("DSIR"), with one R&D Facility located at the Sakarwadi Manufacturing Facility, one located at the Sameerwadi Manufacturing Facility and one located in Navi Mumbai, Maharashtra. As of June 30, 2024, company had engaged 52 permanent research employees including 8 scientists holding doctorates at its R&D Facilities, who seek to identify and develop new potential marketable products after carrying out a thorough study including product specifications, potential products costs and production timeline, based on the leads brought in by company's business development and marketing teams. Company also actively support the agricultural research conducted by the K.J. Somaiya Institute for Applied Agriculture Research ("KIAAR") and have entered into a memorandum of understanding dated September 9, 2021 with KIAAR to carry out joint research activities in various fields including soil testing, production of tissue culture settlings, production and supply of bio-fertilizers, transfer of technology to farmers, organic farming and energy cane. As on the date of this Red Herring Prospectus, company have patented 18 products/processes and received 53 registrations in relation thereto across different countries.

Over the years, company have significantly expanded its scale of operations and global footprint, and during the three months ended June 30, 2024 and Fiscals 2024, 2023 and 2022, company have catered to customers from over 20 countries including Australia, China, Germany, France, Italy Japan, Kenya, Netherlands, Singapore, United Kingdom, United Arab Emirates, Indonesia and United States of America. Company have also established offices in Hoofddorp (Netherlands) and Philadelphia (United States of America), which enables it to assess international demand and increase its customer outreach thereby bolstering its product development initiatives.



GODAVARI BIOREFINERIES LIMITED

INVESTMENT RATIONALE

Company is an integrated bio-refinery in India with an installed capacity of 570 KLPD for manufacturing ethanol as on March 31, 2024	Company is an integrated biorefinery company using sugarcane as a primary feedstock to manufacture a range of products across the value chain including sugar, Ethanol, chemicals, power and other products. According to the Frost & Sullivan Report, among the peers analysed in the Frost & Sullivan Report, Company has the widest portfolio of bio-based products in India. The sugarcane feedstock is processed at company's Sameerwadi Manufacturing Facility for the manufacturing of sugar and Ethanol and press mud is intended to be utilised for the manufacturing of compressed biogas. The bagasse is also used for the generation of power. Company have the ability to divert syrup/juice to produce different grades of ethanol which helps company create optionality between production of sugar and ethanol. In Fiscals 2024, 2023 and 2022, company diverted 27.64%, 42.18% and 36.12% of sugar, either as syrup/ juice or as molasses, towards the manufacturing of Ethanol to take advantage of the EBP Program. According to the Frost & Sullivan Report, only Brazilian mills have this degree of optionality. Such flexibility helps company adapt to changing market dynamics and modify its product mix to optimize realizations and margins.
Well-developed in-house research and development capabilities	The research and development of new products to meet company's customers' requirements is a key growth driver of company's business. Company have three R&D Facilities which are registered with the Department of Scientific and Industrial Research, Government of India ("DSIR") comprising of one R&D Facility located at the Sakarwadi Manufacturing Facility, one located at the Sameerwadi Manufacturing Facility and one R&D Facility located in Navi Mumbai, Maharashtra. Each of company's R&D Facilities is equipped with research and development infrastructure which focuses on the development of new products as well as optimizing company's manufacturing processes. Company regularly monitor and update its research and development capabilities. Company have consistently invested in R&D and technology and have successfully implemented some of the process improvements and product developments at company's Manufacturing Facilities over the years. During the three months ended June 30, 2024 and Fiscals 2024, 2023 and 2022, company have incurred research and development expenditure aggregating to ₹24.84 million, ₹143.50 million, ₹170.06 million and ₹133.62 million respectively, constituting 0.44%, 0.85%, 0.85% and 0.80%, respectively, of company's total expenses.
Company is a manufacturer of Ethanol-based Chemicals and are one of the largest producers of Ethanol in terms of volume	As at June 30, 2024, company had an installed capacity of 570 KLPD for ethanol with capacity utilisation of 2.64%, 46.95%, 46.95% and 58.39% for the three months ended June 30, 2024, Fiscals 2024, 2023 and 2022, while company's revenue from sale of ethanol based on Restated Consolidated Financial Statements during the three months ended June 30, 2024 and Fiscals 2024, 2023 and 2022 was ₹946.01 million, ₹4,821.30 million, ₹5,663.03 million and ₹4,283.48 million. Company's customers for ethanol include oil marketing companies pursuant to the ethanol blended petrol programme of the Government of India (the "EBP Program"). According to the Frost & Sullivan Report, the Indian ethanol market is projected to grow from USD 7.0 billion in 2023 to USD 17.5 billion by 2028, exhibiting a CAGR of 20.0% during 2023-2028, on the back of increasing ethanol use in applications such as fuel additives, disinfectants, and beverages. Company utilise its experience in Ethanol-based chemicals to manufacture a wide range of Bio-based Chemicals including ethyl acetate, bio-ethyl acetate, MPO, 1,3 butylene glycol, crotonaldehyde, acetaldehyde, bio-acetic acid, butanol, EVE, and paraldehyde. Company believe that the Bio-based Chemicals manufactured by its helps company's customers substitute conventional materials without loss of functionality.



GODAVARI BIOREFINERIES LIMITED

OBJECTS OF OFFER

The Offer comprises the Offer for Sale and the Fresh Issue.

The Objects of the Fresh Issue

Company intends to utilise the Net Proceeds from the Fresh Issue towards funding the following objects (the "Objects"):

- 1. Repayment/pre-payment, in full or in part, of certain outstanding borrowings availed by Company; and
- 2. General corporate purposes

RISKS

Company depend on a few suppliers for supply of a significant portion of raw materials (excluding sugarcane). Any failure to procure such raw materials from these suppliers may have an adverse impact on company's manufacturing operations and results of operations.

Source:RHP

INDUSTRY OVERVIEW

Growth Drivers

Increased demand from packaging, pharma, and paints, increasing popularity of bio-based products, and excellent solvent properties are key drivers for Ethyl Acetate usage in India.

The growing market for flexographic and rotogravure printing market: Ethyl acetate has applications as a solvent in inks for flexographic and rotogravure printing, owing to favorable market conditions of flexographic and rotogravure printing the demand for printing inks would increase thereby increasing demand for ethyl acetate.

Growing demand for relevant APIs: Ethyl Acetate is used as an extraction solvent and intermediate in the manufacture of drugs such as sulphamethoxazole, rifampicin, etc.

Bio-based origin helping in 'green solvent' identity: Ethyl Acetate is commercially manufactured using ethanol and acetic Acid. Both raw materials, being obtained from natural sources, ethyl acetate acts as a green solvent. Acetic acid is obtained by bacterial fermentation and ethanol is obtained from molasses.

Optimal properties of the solvent: Ethyl acetate has one of the higher evaporation rates among the solvents. The higher evaporation rate property helps ethyl acetate in reducing the drying time significantly compared to peer solvents. Moreover, it fits in solvent blend mixtures forming azeotropes with fellow solvent blends.

Global and India Ethyl Vinyl Ether Market Overview

Product Overview Ethyl vinyl ether (EVE) is a colorless unsaturated monomer with an ether like odor and low boiling point. With high reactivity, exceptional quality, and good consistency, it is the best choice for a wide range of synthesis including polymerization, addition, and electro cyclic reactions. It can be used as monomer for polymerization, cross-linking monomers, and reactive diluents for UV curing. It is used as a building block for aroma, agrochemicals, lube oil additives, and pharmaceuticals.

Global Market Overview In terms of volume, the global market size for ethyl vinyl ether market was 46.1 KT in 2023 with APAC being the largest consuming region. The market is expected to reach 61.6 KT by 2028 growing with a CAGR of 6.0% from 2023 to 2028. G



GODAVARI BIOREFINERIES LIMITED

Consolidated	Financials
--------------	------------

Consolidated Financials			(Rs in Mn)	
Financials	FY22	FY23	FY24	Q1 FY 2025
Total Revenue (A)	4011.25	4011.25	4011.25	4011.25
Total Expenditure (B)	15694.43	18684.63	15531.3	5347.61
EBIDTA	1328.86	1462.31	1335.35	-122.36
EBIDTA Margin	7.81	7.26	7.92	-2.34
Other Income	76.48	83.85	143.99	
Depreciation				27.48
EBIT	480.25	500.76	599.25	125.72
Interest	925.09	1045.40	880.09	-220.60
PBT	604.40	727.90	755.63	195.74
Share of profit in Asso	320.69	317.50	124.46	-416.34
*	0.00	0.00	0.00	0.00
PBIT	320.69	317.50	124.46	-416.34
Exceptional	0.00	0.00	0.00	0.00
РВТ	320.69	317.50	124.46	-416.34
Tax	129.72	121.14	1.47	-155.29
PAT	190.97	196.36	122.99	-261.05
NPM	1.12	0.97		
ROE%	8.21	7.89	0.73 4.73	-5.00 11.16
EPS	4.55	4.68	2.93	-6.22
Eq Cap				
Net Worth	<u>419.43</u> 4,733.04	<u>419.43</u> 4,894.48	419.43 5,006.80	419.43 4,742.78

Peer Comparison

Face Value	EPS	P/E	ROE %	NAV
10	2.93		4.73	62.05
2.00	29.13	78.84	11.75	247.87
1.00	11.55	64.10	6.68	171.86
2.00	4.46	65.11	6.71	65.18
1.00	50.68	16.69	12.75	397.61
1.00	18.05	26.06	13.62	132.52
1.00	26.49	24.72	15.72	168.57
2.00	33.66	15.83	9.29	362.27
10.00	20.27	11.20	12.21	168.28
1.00	4.44	17.30	10.16	43.66
	10 2.00 1.00 2.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00	$\begin{array}{c cccccc} & 2.93 \\ \hline & & \\ \hline 2.00 & 29.13 \\ \hline 1.00 & 11.55 \\ \hline 2.00 & 4.46 \\ \hline 1.00 & 50.68 \\ \hline 1.00 & 18.05 \\ \hline 1.00 & 18.05 \\ \hline 1.00 & 26.49 \\ \hline 1.00 & 26.49 \\ \hline 1.00 & 20.27 \\ \hline 10.00 & 20.27 \\ \hline 4.44 \end{array}$	$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $



DISCLAIMER

HEM Securities Limited ("Research Entity or HSL") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services, merchant banking services, Portfolio Management Services and other related activities. Broking services offered by HEM Securities Limited are under SEBI Registration No.: INZ000168034.

This Report has been prepared by HEM Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH100002250 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. This should not be construed as invitation or solicitation to do business with HSL. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject HSL and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. HSL reserves the right to make modifications and alterations to this statement as may be required from time to time. HSL or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. HSL is committed to providing independent and transparent recommendation to its clients. Neither HSL nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

HSL and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.